Information for prescribers & healthcare professionals

Developed at Sheba Medical Center by Chief of the Gastroenterology, Professor Shomron Ben-Horin MD, and Director of the Integrative Gastroenterology, Nir Salomon.

  • No prescription needed 
  • No prior authorization needed
  • Delivers to your patients’ door 


What is CurQD®?

CurQD®  is a novel nutraceutical formulation developed by leading IBD researchers and clinically tested at Sheba Medical Center, one of Newsweek’s top 10 hospitals in the world. 

This unique formulation is a blend of gut-directed curcumin and a specifically sourced form of Indigo (Qing Dai, QD). CurQD® was developed into 5 different protocols used successfully in thousands of IBD cases in Israel and around the world, showing exceptional clinical efficacy and safety. 

CurQD® was developed by Nir Salomon, a GI-trained herbalist who heads the Integrative Medicine Unit at Sheba, currently the largest IBD referral center in the country, and Prof. Shomron Ben-Horin M.D, a renowned IBD expert who has trained in Israel and the US, is a member of IOIBD, a previous SciCom member of ECCO, and an Editorial Board member of Gut, APT and JCC.  

CurQD® was licensed to Evinature by the Sheba Medical Center. 



Evinature’s 95% gut-directed curcumin formulation (Cura) was tested in an international multi-center randomized placebo-controlled trial and was found effective as an add-on to 5ASA in inducing remission for mild-mod UC (Lang, CGH 2015). Clinical experience with combination curcumin+QD (CurQD®) has shown efficacy in more severe UC and even in biologic-refractory patients (Ben-Horin S, Case Rep Gastro 2022). 

In a retrospective multi-center study from Israel, CurQD® was recently reported to induce remission in over 65% of active UC patients (Kopylov, UEGW 2022). An international randomized placebo-controlled trial recently found CurQD® to be superior to placebo in inducing remission in active UC patients, including moderate-severe patients who failed biologics (Ben-Horin, CCFA 2023), and Qing Dai was also previously found effective for active UC in another placebo-controlled RCT (Naganuma, Gastroenterology 2018). Evidence for CurQD® efficacy in pediatric patients and in Crohn’s disease is also being accumulated.



  • The recommended dosing of CurQD® is individualized and determined by SCCAI/HBI validated activity scores filled by the patient on the Evinature website assessment page.
  • Blood test for liver enzymes 4-6 weeks after starting QD1 is recommended. In a minority of patients (under 6%), mild elevation of transaminases of up to X5 of ULN can occur, which resolve spontaneously when QD1 is continued at the same dose, or at lower doses. Rarely, QD1 may need to be discontinued because of elevated liver enzymes above X10 ULN. As this is generally unrelated to curcumin (Cura), the Cura component can usually be continued alone.
  • Mild headache can occur in 5-10% of patients starting QD1 and resolves usually within a few days either with continued dosing, reducing the dose for several days, or with temporary 2-3 days halting and resuming CurQD®. 
  • Rare reports from Japan have noted rare cases of PAH in patients who consumed Qing Dai long-term. The condition has not been reported by any patients taking CurQD®. 
  • As an ultimate caution, we advise against using QD1 in patients with a personal or family history of PAH, DVT, or severe cardiovascular, cerebrovascular, or liver disease.
  • Drug interactions with curcumin are uncommon. Web-based interaction sources or our medical team can be consulted if in doubt. Drug interactions of QD1 have not hitherto been reported. 
  • Qing Dai has been rarely associated with ischemic colitis and with colonic intussusception, which may be resolved by stopping Qing Dai and conservative treatment or endoscopic reduction by unprepared colonoscopy with air insufflation.
  • Contraindicated during pregnancy. 

In case of further questions please don’t hesitate to contact us at